Tinengotinib

Tinengotinib
Clinical data
Other names	TT-00420
Identifiers
	IUPAC name 4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-1(14),3,6,8,10,12-hexaen-13-yl]morpholine;
CAS Number	2230490-29-4;
PubChem CID	137279257;
DrugBank	DB17384;
ChemSpider	115008005;
UNII	WZ9TJ0L9Y8;
KEGG	D12545;
ChEMBL	ChEMBL5314430;
Chemical and physical data
Formula	C20H19ClN6O
Molar mass	394.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C2C(=NN1)NC3=CC(=NC=C3C(=N2)C4=CC=CC=C4Cl)N5CCOCC5;
	InChI InChI=InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26); Key:DQFCVOOFMXEPOC-UHFFFAOYSA-N;

Tinengotinib is an investigational new drug that is being evaluated for the treatment of cancer.^[1]

It is an multi-kinase inhibitor designed to target a range of kinases involved in cancer cell proliferation, angiogenesis, and immune response modulation. Specifically, it inhibits fibroblast growth factor receptors (FGFRs) 1–3, janus kinase (JAK) 1/2, vascular endothelial growth factor receptors (VEGFRs), and aurora kinases A/B.^[2]

References